Brett Averso (CTO, EVQLV) and Bhoomika Kumar (SciTech intern, EVQLV) teamed up to provide a high-level overview of how EVQLV’s evolutionary algorithm works.
Month: June 2020
Andrew Satz on the Talent Finders Podcast
EVQLV’s CEO, Andrew Satz, joined Kerrin Black of the Talent Finders Podcast to discuss his entrepreneurial journey, some of the challenges facing AI for drug discovery, his legacy and much more.
How far away is fully computational drug discovery?
Our CEO was recently asked how far away is fully computational drug discovery and development. This isn’t an easy question to answer and Andrew doesn’t provide an exact date. However, he does provide interesting insight into the progress we’ve made and the challenges ahead.
Beyond speed: The value of a computational approach to drug discovery
EVQLV CEO, Andrew Satz, explains that while speed is important, it can also be dangerous, and is certainly not the only reason we’ve chosen a computational approach to drug discovery.
How does EVQLV’s technology work?
Andrew Satz, CEO of EVQLV, explains how our technology works, with specific attention to our progress on COVID-19.